Question explored with the scientific record
Tell me about the shingles vaccine and benefits for dementia how is it for protection against shingles
The shingles vaccine is proven to reduce shingles cases, but the evidence for dementia benefit is not from the retrieved studies.
The two-dose recombinant vaccine (Shingrix) showed about 97% efficacy against shingles in adults aged 50 and older in manufacturer-funded trials, dropping to about 85% by year eight [2][3]. A real-world Medicare study found lower effectiveness, about 70% after two doses [2]. The older live vaccine (Zostavax) reduced shingles by about 51% and postherpetic neuralgia by about 67% in a large placebo-controlled trial of 38,546 adults [1][2]. Both vaccines reduce the painful nerve complication, but the recombinant version is clearly more effective.
| Outcome | Live vaccine (Zostavax) | Recombinant (Shingrix) |
|---|---|---|
| Shingles reduction | ~51% [1] | ~97% (trial), ~70% (real-world) [2] |
| Postherpetic neuralgia reduction | ~67% [1] | ~91% [3] |
| Protection duration | ~5 years | ~8-10 years [2][3] |
The retrieved studies contain no evidence on dementia. The question about dementia benefit is not addressed by any of the 31 records. That claim comes from observational studies outside this retrieval, which are not the same as randomized trials. The safety signal worth noting: the recombinant vaccine carries about 3 excess Guillain-Barré syndrome cases per million doses [2], a small but real risk.
My call: the shingles vaccine works well against shingles, especially the recombinant version, but the dementia claim is not supported by the evidence retrieved here. Confidence in the shingles protection is high; confidence in any dementia benefit is not clear from these records.
Sources used 3
-
Vaccination against Herpes Zoster and Postherpetic Neuralgia
A large randomized, double-blind, placebo-controlled trial in adults aged 60 and older showing that a live attenuated varicella-zoster vaccine reduces the burden of herpes zoster–related illness and postherpetic neuralgia, with substantial reductions in PHN incidence and overall…
DOI: 10.1086/522159 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180